The cost of vision for vitreoretinal interventions

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: This article reviews the current status of treatments for age-related macular degeneration from a cost-effectiveness perspective. RECENT FINDINGS: Treatments are now available to a broad range of patients with age-related macular degeneration, but they are pharmaceutical based and require repeated evaluation and treatment. The resulting unprecedented levels of cost make cost-effectiveness considerations more prescient. Newer methods to evaluate cost-effectiveness and treatment outcomes have included utility and value-based analyses. These have attempted to utilize accurate, objective parameters, but are calibrated by subjective patient assessments and are limited by certain methodological assumptions. Treatment methods to improve outcomes are increasingly being considered within the context of cost-effectiveness. SUMMARY: Although improved understanding of basic, cellular processes has led to markedly improved treatment options for age-related macular degeneration within the past decade, the high costs and wide applicability threaten the balance and viability of the payor system. Accurate means of assessing cost-effectiveness are critical to defining clinical applications.

Original languageEnglish
Pages (from-to)195-201
Number of pages7
JournalCurrent Opinion in Ophthalmology
Volume19
Issue number3
DOIs
StatePublished - May 1 2008

Fingerprint

Cost-Benefit Analysis
Macular Degeneration
Costs and Cost Analysis
Therapeutics
Pharmaceutical Preparations

Keywords

  • Cost utility
  • Cost-effectiveness
  • Vitreoretinal surgery

ASJC Scopus subject areas

  • Ophthalmology

Cite this

The cost of vision for vitreoretinal interventions. / Smiddy, William E.

In: Current Opinion in Ophthalmology, Vol. 19, No. 3, 01.05.2008, p. 195-201.

Research output: Contribution to journalArticle

@article{1a80af6e6a63441a833f797f83534899,
title = "The cost of vision for vitreoretinal interventions",
abstract = "PURPOSE OF REVIEW: This article reviews the current status of treatments for age-related macular degeneration from a cost-effectiveness perspective. RECENT FINDINGS: Treatments are now available to a broad range of patients with age-related macular degeneration, but they are pharmaceutical based and require repeated evaluation and treatment. The resulting unprecedented levels of cost make cost-effectiveness considerations more prescient. Newer methods to evaluate cost-effectiveness and treatment outcomes have included utility and value-based analyses. These have attempted to utilize accurate, objective parameters, but are calibrated by subjective patient assessments and are limited by certain methodological assumptions. Treatment methods to improve outcomes are increasingly being considered within the context of cost-effectiveness. SUMMARY: Although improved understanding of basic, cellular processes has led to markedly improved treatment options for age-related macular degeneration within the past decade, the high costs and wide applicability threaten the balance and viability of the payor system. Accurate means of assessing cost-effectiveness are critical to defining clinical applications.",
keywords = "Cost utility, Cost-effectiveness, Vitreoretinal surgery",
author = "Smiddy, {William E}",
year = "2008",
month = "5",
day = "1",
doi = "10.1097/ICU.0b013e3282fc239f",
language = "English",
volume = "19",
pages = "195--201",
journal = "Current Opinion in Ophthalmology",
issn = "1040-8738",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - The cost of vision for vitreoretinal interventions

AU - Smiddy, William E

PY - 2008/5/1

Y1 - 2008/5/1

N2 - PURPOSE OF REVIEW: This article reviews the current status of treatments for age-related macular degeneration from a cost-effectiveness perspective. RECENT FINDINGS: Treatments are now available to a broad range of patients with age-related macular degeneration, but they are pharmaceutical based and require repeated evaluation and treatment. The resulting unprecedented levels of cost make cost-effectiveness considerations more prescient. Newer methods to evaluate cost-effectiveness and treatment outcomes have included utility and value-based analyses. These have attempted to utilize accurate, objective parameters, but are calibrated by subjective patient assessments and are limited by certain methodological assumptions. Treatment methods to improve outcomes are increasingly being considered within the context of cost-effectiveness. SUMMARY: Although improved understanding of basic, cellular processes has led to markedly improved treatment options for age-related macular degeneration within the past decade, the high costs and wide applicability threaten the balance and viability of the payor system. Accurate means of assessing cost-effectiveness are critical to defining clinical applications.

AB - PURPOSE OF REVIEW: This article reviews the current status of treatments for age-related macular degeneration from a cost-effectiveness perspective. RECENT FINDINGS: Treatments are now available to a broad range of patients with age-related macular degeneration, but they are pharmaceutical based and require repeated evaluation and treatment. The resulting unprecedented levels of cost make cost-effectiveness considerations more prescient. Newer methods to evaluate cost-effectiveness and treatment outcomes have included utility and value-based analyses. These have attempted to utilize accurate, objective parameters, but are calibrated by subjective patient assessments and are limited by certain methodological assumptions. Treatment methods to improve outcomes are increasingly being considered within the context of cost-effectiveness. SUMMARY: Although improved understanding of basic, cellular processes has led to markedly improved treatment options for age-related macular degeneration within the past decade, the high costs and wide applicability threaten the balance and viability of the payor system. Accurate means of assessing cost-effectiveness are critical to defining clinical applications.

KW - Cost utility

KW - Cost-effectiveness

KW - Vitreoretinal surgery

UR - http://www.scopus.com/inward/record.url?scp=42149164270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42149164270&partnerID=8YFLogxK

U2 - 10.1097/ICU.0b013e3282fc239f

DO - 10.1097/ICU.0b013e3282fc239f

M3 - Article

C2 - 18408493

AN - SCOPUS:42149164270

VL - 19

SP - 195

EP - 201

JO - Current Opinion in Ophthalmology

JF - Current Opinion in Ophthalmology

SN - 1040-8738

IS - 3

ER -